Voyager Therapeutics (NASDAQ:VYGR) Shares Cross Below 50-Day Moving Average of $8.27

Voyager Therapeutics, Inc. (NASDAQ:VYGR) crossed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $8.27 and traded as low as $7.55. Voyager Therapeutics shares last traded at $7.59, with a volume of 359,068 shares changing hands.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on VYGR. Oppenheimer reaffirmed an “outperform” rating and set a $18.00 target price on shares of Voyager Therapeutics in a research report on Wednesday, May 15th. Citigroup began coverage on Voyager Therapeutics in a research report on Thursday, March 7th. They set a “buy” rating and a $16.00 target price for the company. Wedbush decreased their target price on Voyager Therapeutics from $10.00 to $8.00 and set a “neutral” rating for the company in a research report on Tuesday, May 14th. HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of Voyager Therapeutics in a report on Thursday, May 16th. Finally, Guggenheim began coverage on Voyager Therapeutics in a research note on Tuesday, March 26th. They set a “buy” rating and a $22.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, Voyager Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

Voyager Therapeutics Stock Up 1.8 %

The firm has a 50 day moving average price of $8.27 and a 200-day moving average price of $8.39.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings data on Monday, May 13th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.24. Voyager Therapeutics had a negative return on equity of 1.28% and a negative net margin of 2.56%. The firm had revenue of $19.52 million during the quarter, compared to analysts’ expectations of $10.33 million. As a group, research analysts anticipate that Voyager Therapeutics, Inc. will post -1.39 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Gladius Capital Management LP purchased a new position in Voyager Therapeutics during the third quarter valued at approximately $25,000. Ameritas Investment Partners Inc. grew its holdings in Voyager Therapeutics by 49.6% in the first quarter. Ameritas Investment Partners Inc. now owns 3,923 shares of the company’s stock valued at $37,000 after purchasing an additional 1,300 shares during the period. Plato Investment Management Ltd acquired a new stake in Voyager Therapeutics in the first quarter valued at approximately $38,000. AJOVista LLC acquired a new stake in Voyager Therapeutics in the fourth quarter valued at approximately $39,000. Finally, China Universal Asset Management Co. Ltd. acquired a new stake in Voyager Therapeutics in the fourth quarter valued at approximately $43,000. 48.03% of the stock is currently owned by hedge funds and other institutional investors.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.